Stiff person syndrome is a rare neurological condition, marked by levels of stiffness and muscle spasms throughout the body, usually in the legs and lower back but often in the arms and trunk.

This document supersedes recommendations in the “2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease.” 5 The scope of this guideline is limited to ...

Coronary Artery Disease; Myocardial Infarction; Epidemiology; Risk Factors; Stroke; Legalisation of medical and recreational cannabis commerce is spreading around the world, associated with increased ...

Learn about restless legs syndrome, its symptoms, causes like iron deficiency and genetics, and treatment options including lifestyle changes and medications.

Peptic Ulcer Disease Diagnosis. Diagnosis of peptic ulcer disease begins with a comprehensive physical exam. You will be asked about your symptoms and medical history. Other diagnostic tests your ...

Ulcerative colitis and Crohn’s disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in ...

His experience highlights how fatty liver disease can suddenly accelerate after years of stability. The progression from manageable condition to advanced cirrhosis demonstrates the unpredictable ...

Familial Hyperchylomicronemia Syndrome Treatment. In December 2024, the FDA approved the first medication for treating FCS. Olezarsen (Tryngolza) is a shot you take under the skin once a month.

Aim To report a 10-year follow-up of patients suffering from severe dry eye syndrome (DES) initially treated with topical ciclosporin A (tCSA) for 6 months. Methods The charts of 26 patients with ...

Otsuka Pharmaceutical has shared more detailed data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio (UPCR ...

An Otsuka drug succeeded in a Phase 3 study in a chronic kidney disease, with results that outperformed a competitor's recent data.

The Centers for Disease Control and Prevention’s plans to consolidate data on diseases like measles and polio are raising concerns about patient privacy, delays in spotting long-term trends and ...